United States v. Michael A. Rosin

263 F. App'x 16
CourtCourt of Appeals for the Eleventh Circuit
DecidedJanuary 16, 2008
Docket06-15538
StatusUnpublished
Cited by7 cases

This text of 263 F. App'x 16 (United States v. Michael A. Rosin) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Michael A. Rosin, 263 F. App'x 16 (11th Cir. 2008).

Opinion

PER CURIAM:

Appellant Michael Rosin, a former dermatologist, once operated a lucrative dermatology practice in Sarasota, Florida. In 2004, his long-time office manager filed a qui tarn action, contending Rosin had defrauded the government by performing hundreds of unnecessary surgeries on elderly Medicare patients. Following a government investigation, Rosin was indicted on 35 counts of health care fraud in violation of 18 U.S.C. § 1347, and 35 counts of making false statements in a health care matter in violation of 18 U.S.C. § 1035. Following a 17-day jury trial, Rosin was convicted on all counts and sentenced to 264 months’ incarceration, restitution in the amount of $3,697,225.38, and forfeiture in the amount of $3,697,225.38.

Rosin appeals his conviction and sentence on myriad grounds, contending his trial was tainted by improper evidence, prejudicial comments by the judge and prosecutor, and misleading jury instructions. Rosin also challenges the substantive and procedural reasonableness of his sentence and the legality of the court’s forfeiture order. Having reviewed the record, we find Rosin’s challenges to be largely without foundation. The trial itself was fundamentally fair, and Rosin’s sentence was reasonable in all respects. Therefore, we affirm.

I. BACKGROUND

From 1983 to 2004, Rosin was the owner and sole physician of a dermatology clinic and laboratory in Sarasota, Florida. He employed an office manager and lab technicians to assist him in his clinical work.

Rosin was trained to perform a specialized form of dermatological surgery called Mohs surgery. The procedure is designed to minimize scarring during the removal of certain types of skin cancer, and is performed in one or more stages. During each stage, the surgeon removes a thin layer of skin and examines it under a microscope, checking the borders for malignancy and mapping the location of any cancer. If a doctor does not see any malignancy, or determines he has removed the outer edge of the malignancy, he stops cutting or proceeds to another section of the skin where the cancer is located. The goal of surgery is to remove all malignant tissue while minimizing the removal of healthy tissue. The surgery is often performed in only one or two stages, but sometimes requires four or more stages to ensure complete removal of the cancer. Due to the time and expertise the surgery requires, it is costly and not appropriate for all patients.

Approximately 95% of Rosin’s patients were elderly Medicare recipients. The federal Medicare program reimburses sur *21 geons for Mohs surgeries at a higher rate than it reimburses for other types of skin cancer removal. The more stages the surgery requires, the higher the Medicaid reimbursement rate. From September 1998 through May 2005, Rosin performed 5,980 skin biopsies. Of these, he reported that 99.43% revealed cancer. During the same period, Rosin billed Medicare for 4,118 Mohs surgeries. He performed four stages of surgery in 98.93% of these cases.

In February 2004, Carolyn Ferrara, Rosin’s office manager, filed a qui tam action, alleging Rosin had defrauded the Government by filing false Medicare claims and performing needless surgeries. Her allegations led to an investigation and, ultimately, to the filing of criminal charges against Rosin.

A. The Trial

At trial, the jury heard testimony from Rosin, government investigators, character witnesses, numerous medical experts, and a number of Rosin’s former employees and patients. The testimony of Rosin’s former employees revealed that Rosin’s laboratory was staffed by poorly trained lab technicians who prepared biopsy slides that were irregular and often unreadable. 'Former employees testified they had altered slides on several occasions, in one case replacing skin tissue with gum, and in another, with styrofoam. According to the employees, Rosin diagnosed cancer on both these slides.

Rosin denied reviewing slides that contained foreign substances. In addition, he challenged the credibility of his former employees, eliciting uncontroverted evidence that several, including Ferrara, had stolen from him during the course of their employment, and stood to benefit financially from the qui tam lawsuit.

The Government called witnesses employed by Florida’s Medicare records contractor to testify regarding the general manner in which Medicare claims are processed and to summarize Rosin’s billing practice. One of these custodians, Julie Kearn, testified that she had compiled data on all of Rosin’s Medicare billings for Mohs surgeries performed from January 2000 to December 2003.

The compiled data was given to Klaus Miescke, a statistician from the University of Illinois at Chicago with experience in health care fraud investigations.

At trial, Miescke testified he used the data Kearns had compiled to select a statistically random sample of 70 surgical slides from which he extrapolated loss findings. The 70 slides Miescke selected were provided to the Government’s medical experts, Drs. Pearon Lang and Franklin Flowers, and to Rosin’s medical experts for review.

Over Rosin’s objection, the Government’s experts testified at trial regarding their own surgical practices, rates of cancer diagnosis, and the percentage of four-stage Mohs surgeries each performed, in addition to offering testimony regarding their review of Rosin’s slides. Three dermatology experts testified on Rosin’s behalf, stating that some of the surgical slides they reviewed had revealed the presence of cancer. Although the experts’ testimony differed with respect to which slides revealed evidence of skin cancer, all agreed the slides were of substandard quality and that many were unreadable.

Pathologist Deborah Bir testified regarding the manner in which surgical slides are typically created, stained, and read. She and Lang testified that the poor quality of Rosin’s surgical slides was unrelated to the age of the slides or the manner in which they had been stored. The defense countered this testimony by arguing the slides had been readable when *22 they were assembled and had deteriorated due to age, poor assembly, or employee sabotage.

In addition to expert testimony, the jury heard from nine character witnesses, who testified Rosin was an honest, charitable, and trustworthy father, doctor, and community member.

In closing argument, the prosecutor argued Rosin’s defense was not credible— that while Rosin claimed to be a caring doctor betrayed by his staff, he was in fact “greedy,” and interested only in making money from the Medicare program, as evidenced by the manner in which he carefully recorded patients’ financial information, but made and retained little information about their medical history and care. The prosecutor pointed out inconsistencies in Rosin’s defense, and called upon jurors to ignore the defense’s “attempts to confuse,” calling Rosin’s theory of the case “misleading” and “unbelievable.”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. John Francis Williams
684 F. App'x 767 (Eleventh Circuit, 2017)
United States v. Stinson
239 F. Supp. 3d 1299 (M.D. Florida, 2017)
United States v. Paul L. Black
678 F. App'x 870 (Eleventh Circuit, 2017)
Michael A. Rosin v. United States
786 F.3d 873 (Eleventh Circuit, 2015)
United States v. Sharp
400 F. App'x 741 (Fourth Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
263 F. App'x 16, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-michael-a-rosin-ca11-2008.